Jeil Pharmaceutical Co Ltd (Jeil), is a pharmaceutical company which carries out research, development, manufacturing and commercialization of active pharmaceuticals and finished dosage forms. Its product portfolio includes solid medicines and injections, finished pharmaceutical products including patches and active pharmaceutical ingredients (APIs). The company reported revenues of (Won) KRW726,393.8 million for the fiscal year ended December 2023 (FY2023), an increase of 0.6% over FY2022.

Generic and Modified Drugs: Jeil Pharmaceutical has a strong foundation in developing high-quality generic drugs and modified new drugs (MNDs). The company utilizes advanced formulation technologies to improve drug delivery and patient compliance. Formulation Technology: The company has a strong focus on formulation technology, including pellet coating, drug release control, and transdermal delivery systems. This enables Jeil to develop innovative dosage forms that address unmet medical needs. Open Innovation: Jeil Pharmaceutical actively collaborates with academic institutions, research organizations, and other pharmaceutical companies to accelerate drug development and expand its product pipeline. Global Expansion: The company is expanding its global footprint through strategic partnerships and licensing agreements.

Public

Pharma, Bio